Eosinophilic Esophagitis- Pipeline Insight, 2018

  • ID: 4330847
  • Drug Pipelines
  • 63 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 4

FEATURED COMPANIES

  • Adare Pharmaceuticals
  • Biotica Pharmaceuticals
  • Celgene
  • GlaxoSmithKline
  • Quorum Innovations
  • Shire
  • MORE
"Eosinophilic Esophagitis- Pipeline Insight, 2018" report outlays comprehensive Insight of present scenario and growth prospects across Eosinophilic Esophagitis. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 10+ products along with 10+ companies involved.

Products covered by Phase
  • Phase III and Phase II
  • Pre-clinical
  • Inactive (Dormant and Discontinued)
Overview of pipeline development activities for Eosinophilic Esophagitis

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Eosinophilic Esophagitis

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
  • Provides an overview of therapeutic pipeline activity for Eosinophilic Esophagitis across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Eosinophilic Esophagitis therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Eosinophilic Esophagitis
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Eosinophilic Esophagitis to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Eosinophilic Esophagitis R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Eosinophilic Esophagitis to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adare Pharmaceuticals
  • Biotica Pharmaceuticals
  • Celgene
  • GlaxoSmithKline
  • Quorum Innovations
  • Shire
  • MORE
Executive Summary
Overview
Eosinophilic Esophagitis
History
Symptoms
Diagnosis
Pathophysiology
Genetics of Eosinophilic Esophagitis
Treatment
Emerging therapies for Eosinophilic Esophagitis
Pipeline Therapeutics
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
SHP621: Shire
Product Description
Research and Development
Product Development Activities
(The list continues)
Mid-Stage Products (Phase II)
Comparative Analysis
Pre-Clinical Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant Products
Comparative Analysis
Appendix

List of Tables:
Table 1: Total Products for Eosinophilic Esophagitis
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Pre-clinical Products
Table 5: Assessment by Route of Administration
Table 6: Assessment by Stage and Route of Administration
Table 7: Assessment by Molecule Type
Table 8: Assessment by Stage and Molecule Type
Table 9: Dormant Products

List of Figures:
Figure 1: Esophagus affected by Eosinophilic Esophagitis
Figure 2: Endoscopy image showing rings, linear and narrow caliber
Figure 3: Pathogenesis of Eosinophilic Esophagitis
Figure 4: Total Products for Eosinophilic Esophagitis
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Pre-clinical Products
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Dormant Products
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adare Pharmaceuticals
  • Atopix Therapeutics
  • Biotica Pharmaceuticals
  • Calypso Biotech
  • Celgene
  • DBV Technologies
  • GlaxoSmithKline
  • Novartis
  • Quorum Innovations
  • Sanofi/Regeneron
  • Shire
  • Teva
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll